AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

Impact · against what's priced in

AEON gains modest positive momentum from completing a necessary regulatory milestone and securing shareholder approval for balance sheet restructuring. The successful vote on the PIPE financing and note exchange reduces solvency concerns and provides the necessary capital to pursue its BOTOX biosimilar pathway.

AEON+0.50

No priced-in read yet